RetinalGenix Technologies Welcomes Dr. Taimour Langaee as Advisor for DNA GPS Pharmacogenetics InitiativesAppointment Underscores RetinalGenix’s Commitment to Integrating the Latest Advances in Genomics and Personalized Medicine into its Product Pipeline
RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabsCompany to use facility to further development of RetinalGenix’s therapies for neurodegenerative and retinal diseases
RetinalGenix Technologies to Participate at the 37th Annual Roth ConferenceCompany will discuss its patented remote monitoring high-resolution retinal imaging system RetinalCam™ and associated biomarker technologies
RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular AnatomyA New Patent Granted for an Affordable and Effective Device and Method To Detect Ocular And Systemic Diseases
RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular DegenerationPETALUMA, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has contracted with MEDsan, Inc. (“MEDsan” to provide diagnostic testing services for its Institutional Review Board (IRB) to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration, which was previously announced on October 30, 2023 (see the link.)
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company’s Medical Advisory BoardPETALUMA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Anatoly Dritschilo, M.D. has joined the Company’s Medical Advisory Board.
RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of DirectorsPETALUMA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Dessislava (Dessy) Boneva, M.D. has joined the Company’s Board of Directors.
RetinalGeniX Technologies Inc. Announces Hiring of Interim CFOVirender Ahluwalia will serve as Interim Chief Financial Officer
RetinalGeniX Technologies Inc. Appoints Stephen Tannenbaum to the Company's Business Advisory BoardPETALUMA, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Stephen Tannenbaum to the Business Advisory Board of RetinalGeniX. Mr. Tannenbaum will provide strategic business advice, consult on potential mergers and acquisitions, and the development of channels to acquire additional capital for the Company.
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam™ Image Visualization DevicePETALUMA, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has contracted with Avania CRO to provide guidance for the Company’s interactions with the FDA for the development of [1] RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD) and [2] RTG-2024 for the treatment of Alzheimer’s syndrome dementia, and [3] the RetinalCam™ image visualization device.
RetinalGeniX IRB Approved to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular DegenerationStudy Intends To Identify Hematology Biomarkers That May Help Personalize Medical Evaluations For Patients Undergoing Treatments For Wet Macular Degeneration
RetinalGeniX Technologies Inc. Focuses on Prevention of Blindness and Early Detection of Multiple Systemic DiseasesVideo Presentation Highlights Combining Genetic Markers with High-Resolution Retinal Imaging to Aid in Detection and Treatment of Blindness and Multiple Systemic Diseases
RetinalGenix Technologies Inc. Announces the Addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPSPETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS™. He will also advise RTGN on its other corporate activities. In this capacity, specifically, he will (a) participate in therapeutic drug selection and development and (b) assist in linking high-resolution retinal imaging (RetinalCam™) both to systemic disease and to DNA-GPS™ pharmacogenetic mapping.
RetinalGeniX Technologies Inc. Granted Patent for Patient Home Monitoring and Physician Alert System for Ocular AnatomyTechnology Enables Physicians to Remotely Make Pre-Diagnostic Assessment Regarding Whether an In-Person Diagnostic Examination of Ocular Anatomy is Warranted
RetinalGeniX Technologies, Inc. Nears Completion of Institutional Review Board for Research on DNA/GPS ProgramStudy Intends To Identify Hematology Biomarkers That May Help Personalize Medical Evaluations For Patients Undergoing Treatments For Macular Degeneration
Retinalgenix Technologies, Inc. Expands Team to Hasten the Launch of DNA/GPSWatson Hired to Accelerate DNA-Based "GPS" Genetic Testing App Which Combines with RTGN's High-Resolution Retinal Imaging Technologies Seeking to Revolutionize Diagnosis of Systemic Diseases
RetinalGeniX Technologies, Inc. to Present at the Emerging Growth Conference Wednesday, October 26, 2022RetinalGeniX Technologies Invites Individual and Institutional Investors, Advisors, and Analysts, to Attend its Real-Time, Interactive Presentation at The Emerging Growth Conference
Vinay Mehindru, MD, MBA Appointed to RetinalGenix Technologies Inc. Board of DirectorsAppointment Expected to Support Initiatives to Improve Population Health Management and the Company’s Planned Listing Upgrade from OTCBQB to NASDAQ
